Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.22.2.2
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine Months Ended September 30, 

​

    

2022

    

2021

    

2022

    

2021

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

Qbrexza®

​

$

6,265

​

$

6,636

​

$

19,752

​

$

11,204

Accutane®

​

​

4,121

​

​

3,531

​

​

14,228

​

​

5,672

Amzeeq®

​

​

1,161

​

​

—

​

​

5,892

​

​

—

Targadox®

​

​

1,168

​

​

5,184

​

​

6,558

​

​

18,110

Ximino®

​

​

1,773

​

​

2,864

​

​

3,775

​

​

6,277

Zilxi®

​

​

554

​

​

—

​

​

1,851

​

​

—

Exelderm®

​

​

1,001

​

​

1,366

​

​

3,018

​

​

4,319

Other branded revenue

​

​

—

​

​

29

​

​

—

​

​

35

Collaboration revenue

​

​

364

​

​

1,446

​

​

1,518

​

​

4,646

Revenue – related party

​

 

48

​

 

29

​

 

118

​

 

252

Other revenue

​

​

73

​

​

—

​

​

2,629

​

 

—

Net revenue

​

$

16,528

​

$

21,085

​

$

59,339

​

$

50,515